Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.
about
Interferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosisGlatiramer acetate for multiple sclerosisOptimizing treatment success in multiple sclerosisOverview of the management of relapsing-remitting multiple sclerosis and practical recommendations.Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisSwitching multiple sclerosis patients with breakthrough disease to second-line therapy.Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?Escalating immunotherapy of multiple sclerosis.Chemotherapeutics in the treatment of multiple sclerosis.A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.Comparative efficacy of switching to natalizumab in active multiple sclerosis.Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational StudyInterferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.Principles of a new treatment algorithm in multiple sclerosis.Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.A method for evaluating treatment switching criteria in multiple sclerosis.Switching therapies in multiple sclerosis.Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response
P2860
Q24194800-C179140B-266B-4A2E-8D85-0C069E61526EQ24235498-39061970-851D-4B92-94AC-D843F0629BBEQ26771968-099B3D86-F022-42DA-8F97-D59E0B034645Q30993770-A280AE2F-CB87-4991-ADC1-FE88E144D042Q33802186-EB4D377E-0A7A-4B79-87DD-9192483D962AQ33815455-F11C7480-4F4E-4F00-ADB0-804617690B70Q33830080-FF5BCD26-456D-44C9-AB6C-2B63B819DFDDQ34409100-EC7128DC-C495-411F-9FCD-C9735E60A091Q34409536-A9DE3253-730B-4456-BA23-479FE9A6D0FEQ34459729-8DF3BBB6-8A26-4CB2-ADA0-2F37A0D08C37Q35469575-808E2F12-4935-4D56-A37D-1D84CBE4793EQ35749670-65BD0AE5-B890-4F50-B897-16CD82670F3DQ35902505-9B5EE820-BA3A-4B16-B089-F3E6AC957849Q36202727-94666FD2-FFD5-4B7D-B215-B50EA3F24483Q37849763-2D248896-4A22-4F15-9BD3-3F26A6E4C9E0Q37976344-CD2E5DD2-10F0-490D-811E-D3AAC5CACB9AQ39021942-F726B83A-CF2A-4528-924B-F330D6BF0DFFQ39672574-22347006-9C06-4CE4-B265-E91C50566922Q42927136-B8D7C8ED-6470-4217-98EA-58C6630F8E9BQ45977173-0C6A85E6-B17F-47B9-B544-AF4D7E790D75Q46835552-EB4D791B-43A2-4E79-B7D1-942273CF6631Q48204088-2439E2E9-7C40-4E74-B1D2-B093F9EEAEC7Q48956772-82E2141F-5D32-4B03-8A70-D6218C2A08CCQ51625833-887BF2B8-E4F3-4B18-904F-0495992C4F86Q57601861-A2011E59-62E4-423E-AE10-A287417BCE1E
P2860
Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Therapeutic outcome 3 years af ...... ltiple sclerosis in Argentina.
@ast
Therapeutic outcome 3 years af ...... ltiple sclerosis in Argentina.
@en
Therapeutic outcome 3 years af ...... ltiple sclerosis in Argentina.
@nl
type
label
Therapeutic outcome 3 years af ...... ltiple sclerosis in Argentina.
@ast
Therapeutic outcome 3 years af ...... ltiple sclerosis in Argentina.
@en
Therapeutic outcome 3 years af ...... ltiple sclerosis in Argentina.
@nl
prefLabel
Therapeutic outcome 3 years af ...... ltiple sclerosis in Argentina.
@ast
Therapeutic outcome 3 years af ...... ltiple sclerosis in Argentina.
@en
Therapeutic outcome 3 years af ...... ltiple sclerosis in Argentina.
@nl
P2093
P2860
P921
P1476
Therapeutic outcome 3 years af ...... ltiple sclerosis in Argentina.
@en
P2093
P2860
P304
P356
10.1111/J.1468-1331.2008.02071.X
P577
2008-04-01T00:00:00Z